Compare New York Times Co (NYT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs TG Therapeutics Inc — how do they compare? New York Times Co trades at $75.56 (market cap $12.29B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: New York Times Co is the larger of the two by market cap, and New York Times Co pays a 1.21% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NYT | TGTX | |
|---|---|---|
Market Cap | $12.29B | $8.26B |
Sector | Media | Health |
52-Week High | $85.86 | $59.06 |
52-Week Low | $51.43 | $26.39 |
Enterprise Value | $11.68B | $8.50B |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYSE: NYT) trades at $74.69, down 1.63% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $2.82 billion in 2025, with net income margin expanding to 12.17%. The stock is supported by strong cash flow from operations of $584 million and a consensus analyst price target of $78.00. Recent news includes the company's motion to quash subpoenas related to reporting on Air Force One, highlighting ongoing legal and press freedom challenges.
Outlook remains positive with consistent earnings growth and a defensive profile amid geopolitical tensions, but risks include regulatory pressures and competitive threats to digital subscriptions. The stock offers a dividend yield with the next payment scheduled for July 23, 2026. Institutional sentiment is mixed with a majority hold rating, suggesting cautious optimism for near-term appreciation toward the price target.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
